COMMUNIQUÉS West-GlobeNewswire

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
17/07/2026
Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
17/07/2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
Orion Group Half-Year Financial Report January–June 2026
17/07/2026
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6 (April–June 2025: 416.5) [...]
BrewDog and Tilray Brands Unlock £1 Million Bar Tab for Football Fans Across England, Scotland and Ireland
17/07/2026
BrewDog and Tilray are keeping football’s biggest celebration alive by unlocking the £1 million bar tab at participating pubs 1 beginning July 20 because great football deserves celebrating, no matter who lifts the [...]
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
17/07/2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect [...]
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/07/2026
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients [...]
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
17/07/2026
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17/07/2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory [...]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
17/07/2026
Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB) Mission will receive up to US$292 million in [...]
Orion Corporation’s financial reporting and Annual General Meeting in 2027
17/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2027 Orion Corporation will publish its Financial Statement [...]
Enjoin Reports 923% Average ROI Delivered in Q1 2026
17/07/2026
Photo Courtesy of Enjoin NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Enjoin, a leading tech-enabled provider of Pre-Bill Chart Reviews and trusted revenue integrity partner to health systems and children's [...]
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/07/2026
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2026 et fait le point sur ses activités
16/07/2026
Châtillon, France, le 16 juillet 2026 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2026 et fait le point sur ses activités Poursuite d’échanges productifs avec la FDA dans le cadre [...]
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
16/07/2026
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® [...]
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
16/07/2026
Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months Proceeds provide additional non-dilutive capital to advance NXT- [...]
Intuitive Announces Second Quarter Earnings
16/07/2026
SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Gyre Therapeutics Appoints Three New Members to its Board of Directors
16/07/2026
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/07/2026
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation
16/07/2026
Châtillon, France, le 16 juillet 2026 DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : [...]

Pages